Stock Monitor: Atrion Post Earnings Reporting
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want access to our free research report on TransEnterix, Inc. (NYSE: TRXC ), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TRXC as the Company's latest news hit the wire. On May 29, 2018, the Company announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for expanded indications of the Company's Senhance Surgical System for laparoscopic inguinal hernia and laparoscopic cholecystectomy (gallbladder removal) surgery. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Atrion Corporation (NASDAQ: ATRI ), which also belongs to the Healthcare sector as the Company TransEnterix. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, TransEnterix most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
This Indication Expansion Immediately Doubles Addressable Market for Senhance in the US
Todd M. Pope, President and Chief Executive Officer of TransEnterix, stated that this indication expansion immediately doubles the addressable market for Senhance in the US and validates the Company's regulatory strategy to successfully add to its indications for use.
According to him, these expanded procedures are commonly performed at over 95% of hospitals in the United States.
Todd added that TransEnterix believes that this indication expansion will significantly increase its applicability to more institutions, particularly those with a busy general surgery practice.
Post announcement of the news, shares of the Company surged in p-remarket trade.
With this Clearance, Senhance System's Total Addressable Annual Procedure in the US has More than Doubled to Over Three Million
There are approximately 760,000 inguinal hernia and 1.2 million laparoscopic cholecystectomy procedures performed annually in the US. With this clearance, Senhance System's total addressable annual procedure in the US has more than doubled to over three million. In the US, Senhance is now cleared for laparoscopic colorectal, gynecologic, inguinal hernia, and cholecystectomy surgery. This enables Senhance to be used for some of the most common abdominal surgeries, including procedures in general surgery and gynecology.
TransEnterix Filed FDA 510(k) Submission for Senhance Indication Expansion in February 2018
The Company filed a FDA 510(k) submission to expand the indication for use of its Senhance ™ Surgical System on February 14, 2018. In collecting the data submitted, TransEnterix leveraged its broad CE mark that included full use in the abdominal and pelvic cavities, and specific uses in the thoracic cavity. The clearance for these expanded indications was expected by mid-year 2018.
TransEnterix Received FDA 510(k) Clearance for Senhance Surgical Robotic System in 2017
In October 2017, TransEnterix received FDA 510(k) clearance for the Senhance ™ Surgical Robotic System. With this clearance, the Senhance became the first new market entrant into the field of abdominal surgical robotics since 2000.
Using the system, a surgeon directs small surgical instruments and a camera with precise movements and comfort. The system builds on the foundation of laparoscopy and features the security of haptic feedback and eye-sensing camera control for the first time in a robotic surgery platform. Additionally, the Senhance utilizes an open architecture, which allows hospitals and surgeons to leverage existing technology investments within the operating room ecosystem.
About TransEnterix, Inc.
Founded in 2006 and headquartered in Morrisville, North Carolina, TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment.
Stock Performance Snapshot
May 30, 2018 - At Wednesday's closing bell, TransEnterix's stock ended the trading session flat at $3.41.
Volume traded for the day: 4.70 million shares, which was above the 3-month average volume of 3.05 million shares.
Stock performance in the last month – up 98.26%; previous three-month period – up 79.47%; past twelve-month period – up 633.02%; and year-to-date - up 76.68%
After yesterday's close, TransEnterix's market cap was at $704.44 million.
The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry. This sector was up 1.4% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES :
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/ .
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.